ACPE Continuing Education Information

Sessions #100A & #100B

Bridging Pharmacy Education and Practice Innovation through Collaboration and Diaspora Engagement

Charles O. Esimone, FAS, FPSN, FNAPharm

At the conclusion of this session, participants will be able to:

1. Critically assess the gaps between pharmacy education and contemporary practice in Nigeria within a global healthcare context.
2. Evaluate the contribution of diaspora and institutional collaborations in advancing pharmacy education and innovation.
3. Propose practical strategies for integrating collaborative models and digital health tools into pharmacy training systems.

Sessions #100A & #100B

Bridging Pharmacy Education and Practice Innovation through Collaboration: Preparing the Next-Generation Pharmacist

Nonye Onyewuenyi, PhD

At the conclusion of this session, participants will be able to:

1. Identify the key structural drivers of the education–practice gap in US pharmacy and articulate their consequences for graduate readiness, patient outcomes, and health-system performance.
2. Evaluate specific collaboration frameworks — academia–industry partnerships, interprofessional education, and digital health curriculum integration — and assess their potential to strengthen pharmacy education and workforce development in the United States.
3. Describe the emerging competencies — clinical decision-making, AI and data literacy, regulatory science, and innovation thinking — required of the next-generation pharmacist, and assess how curricula can be redesigned to deliver them.

YP Session #500 — Building a Borderless Career

Navigating Pharmacy Career Transitions: Pathways from Community Practice to Hospital, Industry, and Leadership

Azuka C. Oparah, PhD

At the conclusion of this session, participants will be able to:

1. Analyze key career decisions that shape diverse global career trajectories.
2. Distinguish between short-term opportunities and long-term strategic career choices.
3. Develop reflective questions to guide future career decision-making in a global context.

Session #700 — Transforming Health-System Pharmacy Practice

Transforming Health-System Pharmacy Practice: Compounding, Access, and Impact in Specialized Patient Care

Ifeanyi Egbunike-Chukwuma, PharmD, BCPS

At the conclusion of this session, participants will be able to:

1. Describe key technology enabled pharmacy services, including telepharmacy and digital care, and their role in improving patient access.
2. Discuss how digital tools enhance medication safety and patient outcomes.
3. Identify strategies to expand pharmacy access in underserved or rural populations through technology enabled solutions.
4. Summarize leadership approaches to advance innovative pharmacy practice and optimize medication use systems within hospitals and health systems.

Session #600 — Keynote Presentation

From Fetal Surgery to Fetal Therapy: Globalizing Innovation Through Science, Access, and Impact

Oluyinka Olutoye, MD, PhD — Keynote Speaker

At the conclusion of this session, participants will be able to:

1. Describe the evolution of fetal therapy from pioneering fetal surgery to contemporary medical, pharmacologic, and genetic interventions.
2. Review emerging transmaternal therapeutic strategies — pharmacologic, biologic, and gene-based — that offer less invasive approaches to treating fetal conditions.
3. Identify opportunities and challenges for implementing accessible fetal therapies in low- and middle-income countries, particularly Nigeria and sub-Saharan Africa.
4. Explore the role of multidisciplinary collaboration, pharmaceutical innovation, and implementation science in expanding equitable access to fetal therapies worldwide.

Sessions #800A & #800B — Developments in Clinical Therapeutics

Dual Targeting, Singular Impact: The Rise of Bispecific Antibodies in Blood Cancer Care

Charlotte Wagner, PharmD, BCOP

At the conclusion of this session, participants will be able to:

1. Describe the mechanism of action of bispecific antibody therapy.
2. Apply safety and monitoring strategies for bispecific antibody therapy.

Sessions #100A & #100B

The Evolving Roles of Community Pharmacists in Value-Based Care

Samuel O. Adekola, FPSN, FNAPharm

At the conclusion of this session, participants will be able to:

1. Explain the principles of value-based care and their implications for community pharmacy practice.
2. Describe the expanding clinical, preventive, and coordination roles of community pharmacists within modern health systems, beyond traditional dispensing functions.
3. Identify practical strategies and priority service areas through which community pharmacists can deliver measurable value in diverse healthcare settings.

Session #200

Globalizing Innovations in Healthcare: Bridging Science, Access, and Impact

At the conclusion of this session, participants will be able to:

1. Analyze key trends shaping the future of healthcare innovation.
2. Describe the challenges and opportunities involved in globalizing healthcare innovation.
3. Identify strategies to improve equitable access to innovative healthcare technologies across diverse health systems and populations.
4. Discuss models for fostering cross-sector partnerships that accelerate the movement from discovery to large-scale implementation and real-world impact.

Session #300

Drug Development and Manufacturing for Access: Innovations That Reduce Cost, Complexity, and Risk

At the conclusion of this session, participants will be able to:

1. Identify current factors contributing to complexity and high cost of new and existing drugs.
2. Apply strategies for integrating quality risk management and realistic drug development goals.
3. Explain applications of seaweeds and natural products in nutrition, nutraceuticals, and human health.
4. Examine the role of seaweeds in renewable energy and environmental sustainability.
5. Describe applications of continuous manufacturing, process analytical technology, automation, and AI in improving pharmaceutical manufacturing and supply chain resilience.
6. Evaluate benefits and challenges of continuous pharmaceutical manufacturing, including real-time release testing, sustainability, regulatory requirements, and workforce readiness.
7. Assess emerging trends in standardization requirements for pharmaceutical products.

Session #400

Pharmacy Business Innovations: Models, Policy, and Technology for Access and Impact

At the conclusion of this session, participants will be able to:

1. Describe emerging pharmacy revenue models beyond traditional dispensing.
2. Explain how technology and artificial intelligence impact retail pharmacy practice.
3. Describe the policy framework and intent behind the Maximum Fair Price (MFP) program.

Session #800A

Repurposing Incretin-Based Therapies for Emerging Indications

Kenneth Izuora, MD, MBA, FACE

At the conclusion of this session, participants will be able to:

1. Describe how incretin-based therapies work and their future integration into broader clinical practice.

Session #800A

Influence of Diet and Diet Quality on Cardiometabolic Health

Jane E.B. Reusch, MD

At the conclusion of this session, participants will be able to:

1. Explain the relationship between dietary patterns and major cardiometabolic risk factors.
2. Recommend evidence-based dietary strategies to improve cardiometabolic health.

Session #800A

Classification, Diagnosis, and Management of Type 5 Diabetes Mellitus

Meredith A. Hawkins, MD

At the conclusion of this session, participants will be able to:

1. Describe the defining clinical and pathophysiological features of type 5 diabetes and how it differs from type 1 and type 2 diabetes.
2. Summarize the evidence supporting undernutrition-associated diabetes as a distinct disease entity and the rationale for its classification as type 5 diabetes.
3. Discuss proposed mechanisms, therapeutic management strategies, and research priorities for type 5 diabetes, particularly in low-income populations.

Session #800B

Acute Chest Syndrome in Sickle Cell Disease

Nkem P. Nonyel, PharmD, MPH, BCPS

At the conclusion of this session, participants will be able to:

1. Describe the molecular and cellular mechanisms underlying acute chest syndrome (ACS) in sickle cell disease.
2. Discuss novel and investigational targeted therapies for ACS.

Learning objectives for remaining individual faculty presentations are being finalized and will be posted here as faculty submissions are approved, prior to the start of each activity.